Oridonin elevates sensitivity of ovarian carcinoma cells to Cisplatin (cas 15603-27-1) via suppressing Cisplatin (cas 15603-27-1)-mediated autophagy
-
Add time:09/02/2019 Source:sciencedirect.com
BackgroundCisplatin (cas 15603-27-1) resistance has been found to contribute to the failure of ovarian carcinoma treatment. Oridonin is a natural en-kaurane tetracyclic diterpenoid compound discovered in Rabdosia rubescene (Henmsl.) Hara. Herein, we tested whether oridonin could exert chemo-sensitization activity on cisplatin-resistant ovarian carcinoma cells.
We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers
Prev:Novel α,β-unsaturated hydroxamic acid derivatives overcome Cisplatin (cas 15603-27-1) resistance
Next:Effect of Cisplatin (cas 15603-27-1) on pancreas and testies in Wistar rats: biochemical parameters and histology) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Review articleThe Cisplatin (cas 15603-27-1)/serum albumin system: A reappraisal09/09/2019
- ReviewPhytochemicals: Current strategy to sensitize cancer cells to Cisplatin (cas 15603-27-1)09/08/2019
- Levosimendan ameliorates Cisplatin (cas 15603-27-1)-induced ototoxicity: Rat model09/07/2019
- Review articleCisplatin (cas 15603-27-1): The first metal based anticancer drug09/06/2019
- Review articleBeyond Cisplatin (cas 15603-27-1): Combination therapy with arsenic trioxide09/05/2019
- ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to Cisplatin (cas 15603-27-1)09/04/2019
- Effect of Cisplatin (cas 15603-27-1) on pancreas and testies in Wistar rats: biochemical parameters and histology09/03/2019
- Novel α,β-unsaturated hydroxamic acid derivatives overcome Cisplatin (cas 15603-27-1) resistance09/01/2019
- Targeting STAT3 inhibition to reverse Cisplatin (cas 15603-27-1) resistance08/31/2019
